Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pulmonx (LUNG)
NASDAQ:LUNG
Pulmonx (LUNG) Stock Price & Analysis
80 Followers
LUNG Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.67 - $14.84
Previous Close$7.9
Volume513.74K
Average Volume (3M)401.91K
Market Cap
$306.64M
Enterprise Value$231.09M
Total Cash (Recent Filing)$116.13M
Total Debt (Recent Filing)$40.57M
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Jul 31, 2024EPS Estimate
-$0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding38,815,760
10 Day Avg. Volume516,276
30 Day Avg. Volume401,909
Standard Deviation0.18
R-Squared0.03
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)2.23
Price to Sales (P/S)3.52
Price to Cash Flow (P/CF)-5.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.17
Enterprise Value/Gross Profit4.55
Enterprise Value/Ebitda-5.87
Forecast
1Y Price Target
$15.25Price Target Upside88.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Pulmonx News
Bulls Say, Bears Say
Bulls Say
InnovationPulmonx has a novel technology for severe emphysema positioned between ineffective medical/lifestyle management and more invasive surgical options with high mortality rates.
ManagementNew management, with experience commercializing novel technologies, has reaffirmed there is no need for a strategic overhaul and will focus on minor optimizations to drive growth.
ValuationPulmonx is among the top 20 projected fastest growing medical device companies in the U.S., yet trades at less than half of this group's average forward EV/Revenue multiple.
Bears Say
Leadership UncertaintyThere is inherent uncertainty that comes with any management change, but the stock's 50% decline since announcing the CEO change does not accurately reflect Pulmonx's underlying fundamentals.
Management ChangeThe unforeseen retirement of long-time CEO Glen French and the resignation of CFO Derrick Sung overshadowed the refocused strategy that reaccelerated 2023 growth.
Stock PerformanceThe stock's 50% decline since announcing the CEO change does not accurately reflect Pulmonx's underlying fundamentals.
---
Ownership Overview
11.01% Insiders
40.06% Mutual Funds
41.53% Other Institutional Investors
7.40% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
ProductionRisks related to the company’s ability to manufacture goods and services
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LUNG FAQ
What was Pulmonx’s price range in the past 12 months?
Pulmonx lowest stock price was $5.67 and its highest was $14.84 in the past 12 months.
What is Pulmonx’s market cap?
Currently, no data Available
When is Pulmonx’s upcoming earnings report date?
Pulmonx’s upcoming earnings report date is Jul 31, 2024 which is in 13 days.
How were Pulmonx’s earnings last quarter?
Pulmonx released its earnings results on May 01, 2024. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.47 by $0.11.
Is Pulmonx overvalued?
According to Wall Street analysts Pulmonx’s price is currently Undervalued.
Does Pulmonx pay dividends?
Pulmonx does not currently pay dividends.
What is Pulmonx’s EPS estimate?
Pulmonx’s EPS estimate is -$0.42.
How many shares outstanding does Pulmonx have?
Pulmonx has 38,815,760 shares outstanding.
What happened to Pulmonx’s price movement after its last earnings report?
Pulmonx reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.47. Following the earnings report the stock price went up 21.503%.
Which hedge fund is a major shareholder of Pulmonx?
Among the largest hedge funds holding Pulmonx’s share is PRIMECAP Management Co. It holds Pulmonx’s shares valued at 53M.
---
Pulmonx Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.25 (88.74% Upside)
$15.25 (88.74% Upside)
Blogger Sentiment
Bullish
LUNG Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 143.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $68.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.39%
12-Months-Change
Fundamentals
Return on Equity
-46.17%
Trailing 12-Months
Asset Growth
-18.23%
Trailing 12-Months
Company Description
Pulmonx
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.
---
LUNG Earnings Call
Q1 2024
0:00 / 0:00
---
LUNG Stock 12 Month Forecast
Average Price Target
$15.25
▲(88.74% Upside)
Technical Analysis
Avanos Medical
―
Lexicon Pharmaceuticals
―
Protagonist Therapeutics
―
Kala Pharmaceuticals
―
Best Analysts Covering LUNG
1 Year
1 Year Success Rate
3/12 ratings generated profit
1 Year Average Return
-17.04%
reiterated a buy rating 3 months ago
Copying Joanne Wuensch's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -17.04% per trade.
---